The rise of theranostics: Part 1 -- Gaining momentum
Since the U.S. Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research.Theranostics pairs diagnostic biomarkers that can be visualized on nuclear medicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. After the therapeutic agent binds to the cancer cells, the tumors are treated in such a way that aims to prevent collateral damage to healthy cells and improve overall outcomes.Theranostics isn’t new; nuclear medicine d...
Source: Headlines - March 26, 2024 Category: Radiology Authors: Liz Carey Tags: Practice Management Molecular Imaging Radiation Oncology/Therapy Nuclear Medicine Source Type: news

What is the Differential Diagnosis of a Suprarenal Mass?
Discussion Suprarenal masses (SRM) are not that common (incidence of 1.9/1000 in neonates), but are more commonly diagnosed prenatally because of prenatal ultrasound. Masses can be difficult to accurately diagnose even after birth because their features overlap. Radiographically they can be variable in size, cystic/solid or mixed and with or without calcifications. Common signs and symptoms of SRM include anemia, jaundice, scrotal hematoma and abdominal mass. Signs of asphyxia may also occur. Often patients whose diagnosis is not clear are monitored closely for a few weeks to see how the lesion changes with time. This is e...
Source: - February 5, 2024 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

US WorldMeds gets FDA approval for childhood cancer drug
More than 700 people are diagnosed with neuroblastoma in the U.S. each year. (Source: Health Care:Pharmaceuticals headlines)
Source: Health Care:Pharmaceuticals headlines - December 18, 2023 Category: Pharmaceuticals Authors: Joel Stinnett Source Type: news

FDA Approves Iwilfin (eflornithine) as Maintenance Therapy for High-Risk Neuroblastoma
LOUISVILLE, Ky.--(BUSINESS WIRE)--USWM, LLC (US WorldMeds) today announced that the U.S. Food and Drug Administration (FDA) has approved Iwilfin™ (eflornithine) 192 mg tablets, a groundbreaking oral maintenance therapy for high-risk... (Source: - New Drug Approvals)
Source: - New Drug Approvals - December 14, 2023 Category: Drugs & Pharmacology Source Type: news

FDA OKs Maintenance Option for High-Risk Neuroblastoma
(MedPage Today) -- The FDA approved oral eflornithine (Iwilfin) for children and adults with high-risk neuroblastoma, the agency announced on Wednesday. Specifically, the ornithine decarboxylase inhibitor is indicated as a maintenance therapy... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 14, 2023 Category: Hematology Source Type: news

Antiparasitic Wins FDA Approval for High-Risk Neuroblastoma Antiparasitic Wins FDA Approval for High-Risk Neuroblastoma
The FDA approved eflornithine to treat this rare cancer in adult and pediatric patients. The drug has also been approved to reduce excessive facial hair growth and to treat sleeping sickness.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - December 14, 2023 Category: Allergy & Immunology Tags: Hematology-Oncology Source Type: news

NIH researchers develop approach that could help supercharge T-cell therapies against solid tumors
Early research in animal models shows potential against cervical cancer and neuroblastoma. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - November 1, 2023 Category: American Health Source Type: news

FDA Panel Endorses DFMO for Kids' High-Risk Neuroblastoma in Remission
(MedPage Today) -- After wrangling all day over semantics and a potential precedent-setting dataset, an FDA advisory committee voted to recommend approval of eflornithine (difluoromethylornithine; DFMO) maintenance for high-risk pediatric neuroblastoma... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 4, 2023 Category: American Health Source Type: news

FDA Advisors to Consider DFMO Maintenance for High-Risk Neuroblastoma in Kids
(MedPage Today) -- An FDA advisory committee on Wednesday will wade into a complicated comparison of a high unmet need in oncology versus uncertainty about whether a drug has "substantial evidence" of effectiveness. At the center of the balancing... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 3, 2023 Category: American Health Source Type: news

Race to save 18-month-old Robin: Cancer-stricken toddler's family are desperately trying to raise £300,000 for potentially life-saving treatment they can't get on the NHS
Robin Samuel was diagnosed with neuroblastoma in January. The toddler from London immediately began chemotherapy, but tests later showed the cancer had spread. (Source: the Mail online | Health)
Source: the Mail online | Health - August 2, 2023 Category: Consumer Health News Source Type: news

Mayo Clinic Q and A:  Cancer of the nerve cells
DEAR MAYO CLINIC: My 4-year-old niece recently was diagnosed with neuroblastoma after not feeling well for a few weeks. Her parents noticed her belly was swollen, so they took her to the doctor after it didn't resolve on its own. I'd never heard of this form of cancer before. What is neuroblastoma? Do children typically have surgery to treat this cancer? What can we expect? ANSWER: Neuroblastoma is a type of cancer that occurs almost only in… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - July 27, 2023 Category: Databases & Libraries Source Type: news

Behind every face is a story telling why the UK must fund trials of child cancer jab
EXCLUSIVE: Around 50 children a year are diagnosed with high-risk neuroblastoma with a 50/50 chance of survival. Solving Kids' Cancer UK is calling on Health Secretary Steve Barclay to meet with them to discuss better treatments. (Source: Daily Express - Health)
Source: Daily Express - Health - July 7, 2023 Category: Consumer Health News Source Type: news

ALK Gene Mutation, Protein Expression in Advanced Neuroblastoma ALK Gene Mutation, Protein Expression in Advanced Neuroblastoma
This study found ALK expression, which can be evaluated in cell blocks from FNAB samples, to be a promising prognostic and predictive marker in advanced neuroblastoma.American Journal of Clinical Pathology (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - May 10, 2023 Category: Surgery Tags: Pathology & Lab Medicine Journal Article Source Type: news

CAR T-Cell Therapy Feasible, Safe in Advanced Neuroblastoma
(MedPage Today) -- Immunotherapy with a chimeric antigen receptor (CAR) T-cell treatment targeting disialoganglioside GD2 may have a sustained antitumor effect in at least a proportion of pediatric patients with relapsed or refractory high-risk... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 6, 2023 Category: Hematology Source Type: news

CAR T Cells Targeting GD2 Feasible, Safe for Pediatric Neuroblastoma
THURSDAY, April 6, 2023 -- Chimeric antigen receptor (CAR)-expressing T cells that target the disialoganglioside GD2 expressed on tumor cells (GD2-CAR T cells) are feasible and safe for children with heavily pretreated neuroblastoma, according to a... (Source: - Pharma News)
Source: - Pharma News - April 6, 2023 Category: Pharmaceuticals Source Type: news